Fri, November 3, 2017

Alethia Young Maintained (ALNY) at Buy with Increased Target to $151 on, Nov 3rd, 2017

Alethia Young of Credit Suisse, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $123 to $151 on, Nov 3rd, 2017.

Alethia has made no other calls on ALNY in the last 4 months.



There are 8 other peers that have a rating on ALNY. Out of the 8 peers that are also analyzing ALNY, 2 agree with Alethia's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $101 on, Thursday, September 21st, 2017


These are the ratings of the 6 analyists that currently disagree with Alethia


  • Rahul Jasuja of "FBR Capital" Maintained at Strong Buy with Increased Target to $240 on, Thursday, November 2nd, 2017
  • Terence Flynn of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Monday, October 2nd, 2017
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $134 on, Friday, September 22nd, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $127 on, Thursday, September 21st, 2017
  • Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017